DiaMedica Therapeutics to Update on Business and Report Q2 2024 Financials August 8, 2024
MINNEAPOLIS--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm, is advancing the development of recombinant KLK1 (DM199) for acute ischemic stroke therapy. The company has announced that it will release its financial results for the second quarter of 2024 after the markets close on Wednesday, August 7th. A live conference call to discuss these results and provide a business update will be held on Thursday, August 8th at 7:00 AM Central Time.
The conference call details are as follows:
- Date: Thursday, August 8, 2024
- Time: 7:00 AM CT / 8:00 AM ET
- Web Access: https://app.webinar.net/RzlwnM9ne8E
- Dial-In Number: (646) 357-8785
- Conference ID: 35082
Participants can join the conference call either by dialing in or through the webcast. It is recommended to log on to the webcast or dial in 15 minutes prior to the start of the call. The webcast will remain accessible for replay on the company's website under the investor relations section, for 12 months following the earnings call. Additionally, a telephonic replay will be available until August 15, 2024, by dialing (888) 660-6345 (US Toll Free) and using the replay passcode: 35082#.
DiaMedica Therapeutics Inc. is dedicated to enhancing the lives of individuals affected by severe ischemic conditions, focusing primarily on acute ischemic stroke and preeclampsia. The company's flagship product, DM199, is the first pharmacologically active recombinant form of the KLK1 protein. This protein has been recognized as an effective treatment in Asia for acute ischemic stroke and other vascular ailments.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
